Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cell-activating cytokines

Surgery (United States)

Volumn 152, Issue 3, 2012, Pages 431-440

  Luedke, Eric ^a   Jaime Ramirez, Alena Cristina ^b   Bhave, Neela ^c   Roda, Julie ^c   Choudhary, Moaz Maqbool ^c   Kumar, Bhavna ^c   Teknos, Theodoros N ^c   Carson III, William E ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RANTES;

ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOMODULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WART VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOKINES; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-12; KILLER CELLS, NATURAL; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84865799326     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2012.05.035     Document Type: Article

References (21)

1. R.I. Haddad, and D.M. Shin Recent advances in head and neck cancer N Engl J Med 359 2008 1143 1154
2. A.D. Colevas Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck J Clin Oncol 24 2006 2644 2652
3. J.B. Vermorken, and P. Specenier Optimal treatment for recurrent/metastatic head and neck cancer Ann Oncol 21 Suppl 7 2010 vii252 vii261
4. O. Dassonville, J.L. Formento, M. Francoual, A. Ramaioli, J. Santini, and M. Schneider Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer J Clin Oncol 11 1993 1873 1878
5. J.B. Vermorken, J. Trigo, R. Hitt, P. Koralewski, E. Diaz-Rubio, and F. Rolland Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy J Clin Oncol 25 2007 2171 2177
6. J.B. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki, and S. Rottey Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 2008 1116 1127
7. J.A. Bonner, P.M. Harari, J. Giralt, N. Azarnia, D.M. Shin, and R.B. Cohen Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
8. G. Trinchieri Interleukin-12 and the regulation of innate resistance and adaptive immunity Nat Rev Immunol 3 2003 133 146
9. R. Parihar, J. Dierksheide, Y. Hu, and W.E. Carson IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells J Clin Invest 110 2002 983 992
10. S.V. Kondadasula, J.M. Roda, R. Parihar, J. Yu, A. Lehman, and M.A. Caligiuri Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma Blood 15 2008 4173 4183
11. A.C. Jaime-Ramirez, B.L. Mundy-Bosse, S. Kondadasula, N.B. Jones, J.M. Roda, and A. Mani IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production J Immunol 186 2011 3401 3409
12. R. Parihar, P. Nadella, A. Lewis, R. Jensen, C. De Hoff, and J.E. Dierksheide A Phase I Study of Interleukin-12 with trastuzumab in patients with HER2-overexpressing malignancies: correlation between response and sustained interferon-gamma production Clin Cancer Res 10 2004 5027 5037
13. T.S. Bekaii-Saab, J.M. Roda, K.D. Guenterberg, B. Ramaswamy, D.C. Young, and A.K. Ferketich A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies Mol Cancer Ther 8 2009 2983 2991
14. J.M. Roda, R. Parihar, C. Magro, G.J. Nuovo, S. Tridandapani, and W.E. Carson Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells Cancer Res 66 2006 517 526
15. J.M. Roda, T. Joshi, J.P. Butchar, J.W. McAlees, A. Lehman, and S. Tridandapani The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines Clin Cancer Res 13 2007 6419 6428
16. D.H. Raulet Interplay of natural killer cells and their receptors with the adaptive immune response Nat Immunol 5 2004 996 1002
17. J.M. Roda, R. Parihar, A. Lehman, A. Mani, S. Tridandapani, and W.E. Carson Interleukin-21 enhances NK cell activation in response to antibody-coated targets J Immunol 177 2006 120 129
18. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat Med 6 2000 443 446
19. Z. Fan, H. Masui, I. Altas, and J. Mendelsohn Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies Cancer Res 53 1993 4322 4328
20. F. Ciardiello, R. Bianco, R. Caputo, R. Caputo, V. Damiano, and T. Troiani Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy Clin Cancer Res 10 2004 784 793
21. A. López-Albaitero, S.C. Lee, S. Morgan, J.R. Grandis, W.E. Gooding, and S. Ferrone Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells Cancer Immunol Immunother 58 2009 1853 1862